SOURCE:

Pressure Biosciences (Otcqb: Pbio): A Tried And True Company With A Proven History And Powerful Product Line Is Now Banging At The Door Of The Very Large Life Sciences Market

Clearwater, FL, United States, via ETELIGIS INC., 10/31/2012 - - Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.

 

With a long-standing reputation in the life sciences community as a company committed to the advancement of sample preparation and molecular biology research, Pressure Biosciences, Inc. (OTCQB: PBIO) has resurfaced in the last year with an abundance of activity, and investors in the biosciences industry should take note.  Selling at .24 cents a share with a market cap of 2.55M and an average volume of 14,363, the company’s stock should be considered, at the very least, a tremendously undervalued investment.

 

Relying on its patented Pressure Cycling Technology (PCT), the company markets pressure-generating based machines which “use cycles of hydrostatic pressure to control bio-molecular interactions.”  According to Pressure Biosciences CEO, Richard T. Schumacher, these machines can safely reach pressure levels several times greater than those found at the deepest levels of any ocean, and PBIO is the first company to ever harness this technology in a laboratory and market it as instruments and consumables.  And with their strong portfolio of 24 issued patents, they just may be the only company to do so well into the future.  

 

Based on the success of this powerful technology, as well as grants totaling nearly a million dollars over the course of the past year, in August the company reported a 70% growth in revenue for the second straight quarter.  Total revenue reported for date ending June 30th, 2012 was $630,569, an enormous increase from the $371,329 reported for the same period in 2011, with the company also seeing a marked increase in the installation of its PCT Sample Preparation Systems.  These PCT Systems are essentially units which utilize the company’s PCT technology to allow scientists ( including forensics specialists like world-famous scientist Dr. Henry Lee) to isolate molecular samples in a laboratory, a process employed by thousands of scientists in a variety of areas, including human cancer and other diseases, soil and plant biology, vaccine development, mass spectrometry, and even counter-bioterror research.

 

With their 24 issued patents and an already impressive list of customers, that includes Harvard, Stanford, the FBI, the US Dept of Agriculture, Amgen, Thermo Fisher, and agricultural giant Monsanto, PBIO continues to grow at an unprecedented rate for a company in its field. 

 

Perhaps the most exciting area of discovery for consumers of PCT technology, however, is that of forensics.  In mid-October, 2012, after extensive studies of PCT technology within the application of forensic DNA analysis, the Harris County Institute of Forensic Sciences in Houston, Texas, as well as the Institute of Applied Genetics at the University of North Texas Health Science Center (UNT) both concluded that PCT can significantly enhance the accuracy of DNA sample results.

 

According to Dr. Bruce Budowle of the Institute of Applied Genetics at UNT:  “We consider our study as a proof of concept that PCT treatment might be a viable method to overcome certain inhibitory effects that can adversely affect DNA testing.  Importantly, it appears that PCT can reduce the effects of inhibitors known to be present in some bone samples, resulting in a marked improvement in DNA testing of these often difficult samples.”

 

Dr. Budowle presented these findings last week at the annual International Symposium on Human Identification in Nashville, TN.  Afterwards, Dr. Nate Lawrence, Vice President of PBI’s Sales and Marketing, announced the company’s intention to “accelerate the development of [its] forensics-based instruments and consumables,” and projected that the increased incorporation of PCT technologies into the field of forensics would result in increased revenue for the company in 2013.

 

The good news is, of course, that the company has already announced other areas that are also expected to increase revenue in 2013.  Nothing like having the ability to put multiple eggs in multiple baskets!

 

After spending years as a research company, Pressure Biosciences, Inc. has stormed into the instruments and consumables market with a force equal to the pressure elicited by its very machines, and has proven both through practice in the field by major companies and via scientific research, that its PCT Platform technology will be a valuable asset to the life sciences industry for years to come.

 

Shareholders looking for a tried and true investment into a significantly undervalued company run by a guy who has had three prior major successes for a relatively small amount of capital need look no further than PBIO.

 

Always read our full disclaimer/disclosure pertaining to this article http://tomorrowsbluechips.com/disclaimer/

 

Seraphim Strategies

922 Mc Mullen Booth Rd

Clearwater FL 33759

727.489.9939

Lou Levenstein

www.tomorrowsbluechips.com

 

SOURCE: Seraphim Strategies Clearwater FL, October 29 2012

 

 

Forward-Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the significant improvement in the detection of DNA in forensic samples with the use of the PCT Platform over other extraction methods; that the PCT Platform could potentially enhance the detection of DNA in forensic samples containing contaminants/inhibitors, specifically bone samples; the Company's plan to speed up the development of its instruments and consumables for commercial forensic use; the conclusions related to the advantages of the PCT Platform reported by the University of North Texas and the Harris Country Institute of Forensic Sciences; that PCT could improve the processing and results of DNA testing and lead to solving crimes that are unsolved today; that the Company will be successful in accelerating the development of its forensic-related instruments and consumables, and that the release of these products will have a positive impact on 2013 revenue; and the size of the life sciences sample preparation market.  These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond December 2012. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond December 2012 on acceptable terms, if at all.  Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Add Comment

Views by Registered Users: 0
Views by Non-Registered Users: 11
Total Like Count: 0
Total Dislike Count: 0
No Comment History